Terminal Disclaimer

Term is cut to match the earlier patent

The disclaimer surrenders any portion of the later patent's term that would extend beyond the expiration of the reference patent. If a continuation would otherwise have lived longer (e.g., because of patent term adjustment), that extra time is gone. The two patents now expire together.

The patents must stay commonly owned

A terminal disclaimer requires that the later patent be enforceable only for the period it and the reference patent are commonly owned. Selling or exclusively licensing one patent away from the other can render the disclaimed patent unenforceable — a serious constraint on splitting a family in a transaction or carve-out.

Enforceability becomes linked

The disclaimed patent and its reference are treated as a linked pair for ownership purposes; you cannot freely separate them. This 'common ownership' tether shapes M&A, divestitures, and patent sales for the life of the patents.

It is effectively irrevocable

Once recorded, a terminal disclaimer generally cannot be withdrawn after the patent issues. The USPTO will sometimes permit withdrawal before issuance on petition if the disclaimer was filed by mistake or is no longer needed, but post-issuance the surrender of term is treated as final. File one only when the rejection genuinely requires it.

Obviousness-type double patenting (ODP) rejection

The primary use. When an examiner rejects claims as an obvious variant of claims in a commonly-owned earlier patent or application (no patentable distinction), a terminal disclaimer overcomes it by removing the unjustified term extension that the doctrine guards against.

Statutory (same-invention) double patenting under § 101

A terminal disclaimer does NOT cure statutory double patenting — where two patents claim the identical invention. That requires actually amending or canceling claims; the disclaimer only addresses the obviousness-type variety.

Continuation and divisional families

ODP rejections most often arise within a family of related applications sharing a specification. Divisionals filed in response to a restriction requirement enjoy a safe harbor under 35 U.S.C. § 121 that can avoid ODP entirely — one reason restriction practice and continuation strategy matter.

Argue distinctness instead

Before disclaiming, consider whether the claims are in fact patentably distinct — arguing distinctness preserves full term and avoids the common-ownership tether. Filing a terminal disclaimer is sometimes a reflexive shortcut where a substantive argument would have kept more value.

What is a terminal disclaimer?

A terminal disclaimer is a statement filed with the USPTO under 37 C.F.R. § 1.321 in which a patent applicant or owner gives up ('disclaims') the portion of a patent's term that would extend beyond the expiration date of another, related patent — and agrees that the disclaimed patent will be enforceable only for so long as it remains commonly owned with that reference patent. Its dominant use is to overcome an obviousness-type double patenting (ODP) rejection during prosecution. The logic: the double patenting doctrine exists to prevent a patentee from effectively extending its exclusivity on an invention by obtaining a second patent on an obvious variant that expires later. A terminal disclaimer neutralizes that concern by (1) forcing the later patent to expire at the same time as the earlier one (removing the unjustified term extension), and (2) requiring the two to stay commonly owned (preventing different parties from separately harassing a defendant with patents covering obvious variants of the same invention). Mechanically it is a short, standard filing with a modest USPTO fee. But its consequences are significant and lasting: it permanently shortens the later patent's term to match the reference, ties the two patents together for ownership purposes, and is effectively irrevocable once the patent issues. Because it is cheap and easy to file, it is sometimes used reflexively — but the term and ownership consequences mean it deserves a deliberate decision, including whether arguing that the claims are patentably distinct would preserve more value.

What is obviousness-type double patenting?

Obviousness-type double patenting (ODP), also called non-statutory double patenting, is a judicially-created doctrine that prohibits a patentee from obtaining a later-expiring patent on claims that are not patentably distinct from — i.e., are obvious variants of — claims in an earlier commonly-owned patent or application. It is distinct from statutory double patenting under 35 U.S.C. § 101, which bars two patents on the identical invention. ODP fills the gap: even if two sets of claims are not identical, allowing a patentee to serially patent obvious variations with staggered expiration dates would improperly extend the term of exclusivity over what is essentially one inventive concept. The analysis resembles an obviousness inquiry: the examiner (or a court) compares the claims of the two patents and asks whether the later claims would have been obvious over the earlier claims. Where they are not patentably distinct, an ODP rejection issues. Two main ways to overcome it: (1) Argue patentable distinctness — show the later claims are meaningfully different, preserving full term and avoiding any ownership tether; or (2) File a terminal disclaimer — accept that the later patent expires with the earlier one and stays commonly owned. ODP has become especially consequential in pharmaceutical patent families and other portfolios with many continuations, and the Federal Circuit has issued significant decisions on how ODP interacts with patent term adjustment (PTA) and patent term extension — an evolving area where a later-filed continuation can sometimes threaten an earlier patent. Because the doctrine turns on common ownership and claim similarity within families, continuation and divisional strategy is where ODP risk is managed.

What do you give up by filing a terminal disclaimer?

Three things, all lasting: (1) Patent term. The disclaimer surrenders any term of the later patent that would have extended beyond the reference patent's expiration. If the later patent (often a continuation) would otherwise have enjoyed a longer life — for example, because of patent term adjustment earned for USPTO delays — that additional exclusivity is permanently forfeited. The two patents now expire on the same day. (2) Freedom to separate the patents. A terminal disclaimer conditions the later patent's enforceability on its remaining commonly owned with the reference patent. This means you generally cannot sell, assign, or exclusively license one without the other and still enforce the disclaimed patent — a real constraint on divestitures, spin-outs, carve-out sales, and even some financing structures, for the entire life of the patents. Splitting a family that contains terminally-disclaimed patents requires careful structuring or the disclaimed patent may become unenforceable. (3) Practical reversibility. Once the patent issues, a terminal disclaimer generally cannot be undone; the surrendered term does not come back. (Before issuance, the USPTO may grant a petition to withdraw a disclaimer filed in error or no longer needed, but this is not guaranteed.) What you do NOT give up: the validity or scope of the claims themselves — the disclaimer is about term and ownership, not claim coverage. The strategic point is that a terminal disclaimer is the right tool when the claims truly are obvious variants and you want them issued, but it is not free: the alternative of arguing patentable distinctness, where credible, preserves both full term and ownership flexibility.

Does a terminal disclaimer admit that the claims are obvious?

Filing a terminal disclaimer to overcome an obviousness-type double patenting rejection is generally NOT treated as an admission that the claims are obvious in the prior-art sense (under 35 U.S.C. § 103) or otherwise unpatentable. The USPTO's Manual of Patent Examining Procedure reflects the position that filing a terminal disclaimer to obviate an ODP rejection does not constitute an admission of obviousness of the claimed invention over the prior art. The two inquiries are different: an ODP rejection compares the later claims to the earlier patent's CLAIMS (a special analysis aimed at preventing unjustified term extension within a commonly-owned family), whereas § 103 obviousness compares the claims to the PRIOR ART. Overcoming the former by disclaimer says nothing about the latter. That said, practitioners remain mindful that statements made during prosecution become part of the record, so the response accompanying a terminal disclaimer should be drafted carefully and should not contain language conceding obviousness over prior art. A separate, evolving consideration: courts have examined how terminally-disclaimed patents fare when the reference patent is later invalidated — and the relationship between disclaimed patents and the validity of their references has been the subject of significant Federal Circuit attention, making it important to track current case law for families that rely heavily on terminal disclaimers. The short answer for most applicants: a terminal disclaimer overcomes ODP without admitting prior-art obviousness, but the surrounding prosecution statements and the downstream validity interactions still warrant care.

How do I avoid needing a terminal disclaimer in the first place?

Several strategies reduce or eliminate ODP exposure across a patent family: (1) Use the § 121 safe harbor for divisionals. When the USPTO issues a restriction requirement forcing you to split distinct inventions into separate applications, claims in a divisional filed in response to that restriction are protected by 35 U.S.C. § 121 from being used in an ODP rejection against the parent (and vice versa), provided the divisional is filed as a consequence of the restriction and consonance is maintained. Proper divisional practice can thus avoid ODP entirely — one reason restriction requirements, though annoying, can be strategically useful. (2) Draft claims to be patentably distinct across family members. If continuations pursue genuinely different inventive aspects (different claim scope, different statutory category, meaningfully different limitations) rather than obvious variants, ODP may not arise. (3) Manage filing sequence and term. Because ODP interacts with patent term adjustment and expiration dates, the order and timing of filings, and which application carries which term, can affect whether a disclaimer becomes necessary and how much term it would cost — worth modeling in valuable families. (4) Argue distinctness before disclaiming. When an ODP rejection issues, evaluate a substantive distinctness argument before reflexively filing a disclaimer; winning the argument preserves full term and ownership flexibility. (5) Be deliberate in pharma and other long-tail portfolios. In fields where families run to dozens of patents and term is extremely valuable, ODP and terminal disclaimer strategy is a core part of portfolio planning, often involving specialized counsel — because a poorly-considered disclaimer can forfeit years of exclusivity or entangle the family for a future divestiture. The overarching principle: a terminal disclaimer is a fix, not a plan; the better outcome is a family structured so the fix isn't needed.